Please see full prescribing and safety information, including boxed warning, for MIDAZOLAM single-dose vials and multi-dose vials.
Available in:
- 2 mg per 2 mL single-dose vials*
- 50 mg per 10 mL multi-dose vials
Benefits:
- AP Rated
- Not made with natural rubber latex
- *Preservative-free
Downloads:
MIDAZOLAM Injection, USP*
Therapeutic Category: Benzodiazepine
PreventIV Measures® Features:
- Easy-to-read drug name and dosage strength to aid in identifying the right product
- Bar codes included on the vial and carton for ease of scanning
- Unique label design to help products stand out on the shelf
- Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
| NDC #25021 |
Description | Strength | Fill Volume |
Concentration | Container Size |
Closure | Unit of Sale |
| 655-02* | Amber Glass Vial | 2 mg | 2 mL | 1 mg per mL | 2 mL | 13 mm | 10 |
| 661-10 | Amber Glass Vial | 50 mg | 10 mL | 5 mg per mL | 10 mL | 20 mm | 10 |
*Preservative-free
WARNINGS
Personnel and Equipment for Monitoring and Resuscitation Adults and Pediatrics: Intravenous midazolam hydrochloride has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Intravenous midazolam hydrochloride should be used only in hospital or ambulatory care settings, including physicians’ and dental offices, that provide for continuous monitoring of respiratory and cardiac function, e.g., pulse oximetry. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured (see WARNINGS). For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure. Risks From Concomitant Use With Opioids Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation (see WARNINGS and PRECAUTIONS, Drug Interactions). Individualization of Dosage Midazolam hydrochloride must never be used without individualization of dosage. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a normal healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients and in patients receiving concomitant narcotics or other central nervous system (CNS) depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg per mL formulation or dilution of the 1 mg per mL or 5 mg per mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg per kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent (see DOSAGE AND ADMINISTRATION for complete dosing information) Neonates: Midazolam should not be administered by rapid injection in the neonatal population. Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant use of fentanyl (see DOSAGE AND ADMINISTRATION for complete information).